Adding ibrutinib to indoximod and chemo for young people with brain cancer
Original title: Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test to find a safe dose in a small number of people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial tests a drug called ibrutinib added to treatment young people with brain cancer are already being given in studies.
Who this trial is for. This trial is for people age 6 to 25 years with primary brain cancer that came back or did not respond to treatment. It tests the drug ibrutinib given with indoximod and pills for chemotherapy.
Where it stands. The trial has not reported results. Its main goal is to find the best safe dose of ibrutinib with each treatment plan. Later groups will look for early signs of whether the mix helps. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: This is one of the places where new options for brain cancer that came back are being tested. If you or your child fits the age and the type of cancer, you could ask your care team about it. They can tell you if it makes sense for your situation.
What it doesn't mean: This does not mean the treatment works. A trial is a test, not a proven treatment. Joining one is not a guarantee that it will help you. It is not a promise of a cure. The trial team decides who can take part.
Source: ClinicalTrials.gov, November 2, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.